Sequella, Inc., a clinical stage biopharmaceutical company, develops products for the diagnosis and treatment of infectious diseases. The company focuses on commercializing treatment paradigms for diseases of epidemic potential. It develops TB Patch for the diagnosis of active TB; SQ109 for the treatment of TB; drug compliance monitor, a device for application in multiple drug therapies; SQ609 for the treatment of Crohn’s disease, TB, SARS, and other anti-viral; Heat Shock Protein, an adjuvant therapy for TB drug; and translocase inhibitor for the treatment of TB, and other anti-infective disease. The company also engages in identifying and developing drug candidates for SARS, candidiasis, and ulcers. Sequella, Inc. was founded in 1997 and is based in Rockville, Maryland.